Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Luspatercept for the treatment of myelodysplastic syndrome: A retrospective cohort study utilizing trinetx

View Full Paper
Ask AI
Bookmark
Share

Authors

SWShanawar WarisLVLauren VeltriKSKonstantinos Sdrimas

Discussion

Loading...

Member takes

Overview

Retrospective cohort study assessed luspatercept efficacy in anemia treatment of MDS, indicating potential benefits for patients.

Key Points

  • The study aims to assess the safety and efficacy of luspatercept in treating anemia in patients with myelodysplastic syndrome (MDS).
  • Retrospective cohort study utilizing data from the TriNetX network.
  • Evaluated patients with very low- to intermediate-risk MDS who were ESA refractory.
  • Primary outcome: red blood cell transfusion independence at multiple time points.
  • Achieved RBC-TI rates were 28.5%, 21.0%, and 11.0% at 8 weeks, 16 weeks, and 1 year, respectively.
  • 17% of patients progressed to hypomethylating agent therapy within the first year.
  • Survival analysis indicated a 1-year overall survival probability of 73.3%.

Cite This Study

Waris et al. (2025) studied this question.

synapsesocial.com/papers/69362f5d4fa91c937236dc08https://doi.org/10.1182/blood-2025-7373
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Experience with luspatercept therapy in patients with transfusion-dependent low-risk myelodysplastic syndromes in real-world clinical practice: exploring the positive effect of combination with erythropoietin alfa2024 · 7 citations
  2. 2The efficacy and safety of luspatercept in patients with low-blasts myelodysplastic neoplasms in real world2025
  3. 3Clinical benefit of luspatercept treatment (tx) in transfusion-dependent (TD), erythropoiesis-stimulating agent (ESA)–naive patients (pts) with very low-, low- or intermediate-risk myelodysplastic syndromes (MDS) in the COMMANDS trial.2024 · 2 citations
  4. 4Luspatercept for Patients with Lower-Risk Myelodysplastic Syndromes/Neoplasms: A Systematic Review and Meta-Analysis2025 · 4 citations
  5. 5Real-world treatment patterns and outcomes of first-line luspatercept in patients with myelodysplastic syndromes in the United States2025 · 1 citations